School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510006, Guangdong Province, China.
Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, 510006, Guangdong Province, China.
Plant Foods Hum Nutr. 2024 Dec;79(4):834-842. doi: 10.1007/s11130-024-01215-5. Epub 2024 Aug 17.
Chickpea is rich in protein and has been demonstrated to possess hypoglycaemic effects. However, the specific bioactive ingredients and mechanisms underlying their hypoglycaemic effects remain unclear. In this study, enzymatic hydrolysis and gel permeation chromatography were used to extract chickpea bioactive peptide (CBP) from chickpea protein. One of the products, CBP-75-3, was found to inhibit α-glucosidase (GAA) activity and significantly increase the viability of insulin resistant (IR) cells. Moreover, CBP-75-3 significantly increased the rate of glucose consumption and glycogen synthesis in IR-HepG2 cells. Moreover, CBP-75-3 decreased the levels of malondialdehyde and increased the levels of superoxide dismutase, glutathione, and glutathione peroxidase. Subsequently, 29 novel bioactive peptides in CBP-75-3 were identified by LC‒MS/MS, and the potential hypoglycaemic targets of these novel bioactive peptides were investigated using molecular docking. Based on the results, the residues of the novel bioactive peptides interact with GAA through hydrogen bonding (especially LLR, FH, RQLPR, KGF and NFQ by binding to the substrate binding pocket or the active centre of GAA), thereby inhibiting GAA activity and laying a foundation for its hypoglycaemic activity. In short, the novel bioactive peptides isolated and identified from chickpea can effectively exert hypoglycaemic effects and increase the antioxidant capacity of IR-HepG2 cells. This study reveals that CBP-75-3, a natural hypoglycaemic ingredient, has potential for applications in functional foods and provides a theoretical basis for the development and application of CBP in the future.
鹰嘴豆富含蛋白质,并已被证明具有降血糖作用。然而,其降血糖作用的具体生物活性成分和机制仍不清楚。在这项研究中,采用酶解和凝胶渗透色谱法从鹰嘴豆蛋白中提取鹰嘴豆生物活性肽(CBP)。其中一种产物 CBP-75-3 被发现能抑制α-葡萄糖苷酶(GAA)活性,并显著提高胰岛素抵抗(IR)细胞的活力。此外,CBP-75-3 能显著提高 IR-HepG2 细胞的葡萄糖消耗率和糖原合成率。此外,CBP-75-3 降低了丙二醛的水平,增加了超氧化物歧化酶、谷胱甘肽和谷胱甘肽过氧化物酶的水平。随后,通过 LC-MS/MS 鉴定了 CBP-75-3 中的 29 种新型生物活性肽,并通过分子对接研究了这些新型生物活性肽的潜在降血糖靶点。基于这些结果,新型生物活性肽的残基通过氢键与 GAA 相互作用(特别是通过与 GAA 的底物结合口袋或活性中心结合的 LLR、FH、RQLPR、KGF 和 NFQ),从而抑制 GAA 活性,为其降血糖活性奠定基础。总之,从鹰嘴豆中分离和鉴定的新型生物活性肽能有效发挥降血糖作用,并提高 IR-HepG2 细胞的抗氧化能力。本研究揭示了鹰嘴豆 CBP-75-3 作为一种天然降血糖成分,具有在功能性食品中应用的潜力,为 CBP 的开发和应用提供了理论依据。